Immutep, Prima BioMed deal

Prima BioMed completed its acquisition of Immutep for up to $25 million in cash, shares and warrants. Prima BioMed attributed the difference from the original $28 million price “to the reduction in value of the warrants based on the Black Scholes option pricing model” (see BioCentury, Oct. 20, 2014). ...